Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD20 therapy in severe, conventional therapy-resistant endocrine orbitopathy
2006-006099-39Phase 2Completed
- Sponsor
- University of Debrecen
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Graves Orbitopathy (GO), sponsored by University of Debrecen. Primary endpoint: Safety and tolerability at day 90. Started Nov 2006; status: completed.
02
Drugs
rituximab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2006-006099-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006099-39.